Tag Archives: first

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma to challenge Roche’s Polivy

The FDA hasn’t specifically approved a therapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after an initial line of therapy—until now. MorphoSys and Incyte’s Monjuvi—also known as tafasitamab—in combination with Celgene’s Revlimid now represents the first FDA-approved second-line regimen for DLBCL, the two companies said Friday. Because of Monjuvi’s importance… Read More »

Healthcare sector added 358K jobs, hospitals had first gains in 2 months

Dive Brief: The healthcare sector added 358,000 jobs throughout the last two weeks of May and the first two weeks of June, according to the U.S. Bureau of Labor Statistics monthly jobs report. Similar to last month’s report, dentists and physician’s offices saw notable gains: 190,000 and 80,000 jobs added, respectively.​ Hospitals added about 7,000 jobs,… Read More »

Coronavirus UK: Health workers and at-risk to get vaccine first

Frontline NHS and social care workers, over-50s and Brits with heart or kidney disease will get Covid-19 vaccine first when it becomes available, Matt Hancock reveals Health Secretary made the announcement in Downing Street press conference Mr Hancock said the advice would allow Britain to ‘protect the most at-risk first’  Imperial College London started human… Read More »

Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

Print this page June 1, 2020 — AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease. The approval by the US Food and Drug Administration (FDA) was based on… Read More »